Viking Therapeutics, Inc. (0VQA.L)
0VQA.L Stock Price Chart
Explore Viking Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze 0VQA.L price movements and trends.
0VQA.L Company Profile
Discover essential business fundamentals and corporate details for Viking Therapeutics, Inc. (0VQA.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
8 Oct 2018
Employees
45.00
CEO
Brian Lian
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
0VQA.L Financial Timeline
Browse a chronological timeline of Viking Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 21 Apr 2026
Upcoming earnings on 3 Feb 2026
Upcoming earnings on 21 Oct 2025
Upcoming earnings on 22 Jul 2025
Earnings released on 23 Apr 2025
EPS came in at -$0.41 falling short of the estimated -$0.33 by -24.13%.
Earnings released on 5 Feb 2025
EPS came in at -$0.32 falling short of the estimated -$0.28 by -16.01%.
Earnings released on 24 Oct 2024
EPS came in at -$0.22 surpassing the estimated -$0.24 by +7.41%.
Earnings released on 25 Jul 2024
EPS came in at -$0.20 surpassing the estimated -$0.26 by +23.26%.
Earnings released on 25 Apr 2024
EPS came in at -$0.26 surpassing the estimated -$0.28 by +4.43%.
Earnings released on 26 Mar 2024
EPS came in at -$0.25 surpassing the estimated -$0.25 by +3.26%.
Earnings released on 26 Oct 2023
EPS came in at -$0.23 falling short of the estimated -$0.22 by -3.04%.
Earnings released on 27 Jul 2023
EPS came in at -$0.19 falling short of the estimated -$0.19 by -0.75%.
Earnings released on 27 Apr 2023
EPS came in at -$0.25 falling short of the estimated -$0.24 by -3.79%.
Earnings released on 9 Feb 2023
EPS came in at -$0.26 falling short of the estimated -$0.23 by -9.95%.
Earnings released on 30 Sept 2022
EPS came in at -$0.21 surpassing the estimated -$0.23 by +11.52%.
Earnings released on 30 Jun 2022
EPS came in at -$0.23 falling short of the estimated -$0.21 by -7.01%.
Earnings released on 26 Apr 2022
EPS came in at -$0.21 falling short of the estimated -$0.19 by -8.34%.
Earnings released on 15 Feb 2022
EPS came in at -$0.16 surpassing the estimated -$0.19 by +14.09%.
Earnings released on 3 Nov 2021
EPS came in at -$0.20.
Earnings released on 30 Sept 2021
EPS came in at -$0.17.
Earnings released on 31 Mar 2021
EPS came in at -$0.19.
Earnings released on 31 Dec 2020
EPS came in at -$0.15.
Earnings released on 30 Sept 2020
EPS came in at -$0.13.
0VQA.L Stock Performance
Access detailed 0VQA.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.